Latest Conference Articles

Neoadjuvant atezolizumab followed by surgery led to a major pathologic response in 21% of patients with resectable stage IB-IIIB non–small cell lung cancer, according to findings from the primary analysis of the LCMC3 trial.

Nivolumab is an effective treatment approach for patients with previously treated malignant mesothelioma according to data from the phase 3 CONFIRM trial.

Luis E. Raez, MD, discusses the treatment of TRK fusion-positive lung cancers in the past and the present.

One retrospective study from Spain quantified the impact the COVID-19 pandemic has had in 2020 on lung cancer diagnosis and prognosis.

In patients with EGFR-mutated non–small cell lung cancer, adjuvant treatment with osimertinib in the pivotal phase 3 ADAURA trial led to improvement in disease-free survival, irrespective of previous adjuvant chemotherapy received or disease stage.

Lyudmila A. Bazhenova, MD, explains the impact of having larotrectinib results in a lung cancer cohort, as seen in a presentation of data from 14 patients, given during the 2020 World Conference on Lung Cancer Singapore.

Antitumor activity was demonstrated with trastuzumab deruxtecan treatment in patients with HER2-overexpressing non–small cell lung cancer, regardless of HER2 expression levels, according to interim findings from a cohort of the phase 2 DESTINY Lung-01 trial.

Progression-free survival and overall survival benefits, combined with a higher objective response rate, confirmed the noninferiority of nab-paclitaxel compared with docetaxel in previously treated patients with advanced non–small cell lung cancer, according to phase 3 trial results.

Antitumor activity was seen in the combination of pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer, regardless of PD-L1 status or tumor histology.

Treatment with amivantamab induced deep and durable responses as well as promising survival as treatment of patients with previously treated non–small cell lung cancer harboring EGFR exon 20 insertion mutation in phase 1 CHRYSALIS trial.

Patients with checkpoint inhibitor-naïve and refractory composite AXL-positive non—small cell lung cancer, responded to treatmen with the first-in-class oral kinase inhibitor bemcentinib in combination with pembrolizumab, and the compound was well-tolerated, according to updated results from the phase 2 BGBC008 clinical trial.

Sotorasib demonstrated significant benefit in patients with KRAS G12C–mutated advanced non–small cell lung cancer, according to results from the phase 2 portion of the CodeBreaK 100 trial to be presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer.

Zev A. Wainberg, MD, discusses the impact of the COVID-19 on the colorectal cancer field specifically in terms of clinical trial research.

In the phase 1 RESILIENT trial, patients with small cell lung cancer who failed platinum-based treatment in the first-line setting, displayed encouraging anti-tumor activity and safety, results presented during the 2020 World Conference on Lung Cancer show.

John L. Marshall, MD, discusses factors to consider when prescribing third line therapy for colorectal cancer in a discussion with Targeted Oncology.

In patients with relapsed/refractory small cell lung cancer who did not receive previous checkpoint inhibitor therapy, the addition of the anti–fucosyl-GM1 monoclonal antibody, BMS-986012 to nivolumab demonstrated promising results in a phase 1/2 study.

A correlation between the emergence of immune-related adverse events and presence of mutations was identified in patients with non-small lung cancer receiving immunotherapy.

Long-term follow-up results from KEYNOTE-042 show that pembrolizumab continues to improve survival and response outcomes in patients with PD-L1+ locally advanced or metastatic non–small cell lung cancer.

Overall survival is significantly improved when pembrolizumab is added to platinum-based chemotherapy in the frontline treatment of patients with metastatic nonsquamous non-small cell lung cancer.

Five years of follow-up in KEYNOTE-010 reveals that pembrolizumab can maintain improvement in survival over docetaxel in a non–small cell lung subgroup.

In pretreated patients with advanced small cell lung cancer, treatment with the combination of apatinib and single-agent chemotherapy showed promising efficacy and was well-tolerated, data from a prospective phase 2 study.

Tanios S. Bekaii-Saab, MD, discusses genetic testing and emerging precision medicine strategies in the field of colorectal cancer.

The triplet regimen of nivolumab, ipilimumab, and panitumumab has shown antitumor activity among patients with previously treated metastatic colorectal cancer that is microsatellite stable and KRAS, NRAS, and BRAF wild-type, according to findings from a phase 2 LCCC1632 study.

Kanwal Raghav, MBBS, MD, discusses factors that should be considered when deciding on treatment for a patient with metastatic colorectal cancer.

The overall health-related quality of life among younger patients with colorectal cancer is poorer as incidence in patients under the age of 50 increases, with social and functional well-being suffering more with longer treatment durations.

Pembrolizumab monotherapy demonstrated durable antitumor activity and encouraging effects on survival in an evaluation of patients with previously untreated hepatocellular carcinoma.

In patients with previously treated advanced hepatocellular carcinoma (HCC), single-agent pembrolizumab (Keytruda) maintained numerical improvement in survival (OS), updated findings randomized phase 3 KEYNOTE-240 trial show.

Results from the phase 3 IMbrave150 clinical trial showed that the combination of atezolizumab and bevacizumab continued to demonstrate improvement in survival compared with sorafenib in previously untreated patients with advanced hepatocellular carcinoma.

In a phase 2 clinical trial, the oral, FGFR1-3 selective tyrosine kinase inhibitor, infigratinib correlated with promising anticancer activity in addition to manageable safety as treatment of patients with chemotherapy-refractory cholangiocarcinoma whose tumors harbor FGFR2 fusions.

The final overall survival analysis of the phase 3 ClarIDHy trial demonstrated that treatment with ivosidenib tablets achieved a 21% reduction in the risk of death in patients with IDH1-mutant cholangiocarcinoma compared with placebo.